{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:14:18Z","timestamp":1788318858796,"version":"build-2803163510"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>The safety of KPI-121 0.25%, an ophthalmic nanoparticle suspension of loteprednol etabonate, was evaluated in subjects with dry eye disease (DED) in one phase 2 and three phase 3 randomized trials of similar design.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Adults with DED received KPI-121 0.25% or vehicle drops 4 times daily (QID) for \u22652 weeks; 1430 subjects received KPI-121 0.25% and 1438 subjects received vehicle drops. Main safety assessments were adverse events (AEs) and intraocular pressure (IOP). As a common side effect associated with the use of ocular corticosteroids is elevated IOP, subjects with a history of or current diagnosis of glaucoma were excluded.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Instillation site pain was the most common AE, reported by 5.2% of subjects in the KPI-121 0.25% group and 4.4% of subjects in the vehicle group; other AEs were reported by \u22640.8% of subjects in the KPI-121 group. IOP elevations, a side effect associated with the use of ophthalmic corticosteroids, were observed with low incidence: 0.6% and 0.2% of subjects in the KPI-121 and vehicle groups, respectively. An IOP elevation was defined as an increase from baseline of &gt;5 mm Hg that resulted in an IOP of \u226521 mm Hg in either eye during use of the study product.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>KPI-121 ophthalmic suspension 0.25% seemed to be safe and well tolerated when dosed QID for 2 to 4 weeks in those DED subjects included in the 4 trials.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ico.0000000000002452","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T14:01:38Z","timestamp":1598018498000},"page":"564-570","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":45,"title":["Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A Pooled Analysis of 4 Multicenter, Randomized, Vehicle-Controlled Studies"],"prefix":"10.1097","volume":"40","author":[{"given":"Michael","family":"Korenfeld","sequence":"first","affiliation":[{"name":"Comprehensive Eye Care, Ltd, Washington, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly K.","family":"Nichols","sequence":"additional","affiliation":[{"name":"School of Optometry, University of Alabama, Birmingham, AL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Wolstan and Goldberg Eye Associates, Torrance, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Evans","sequence":"additional","affiliation":[{"name":"Total Eye Care, PA, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Sall","sequence":"additional","affiliation":[{"name":"Sall Research Medical Center, Artesia, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Foulks","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Louisville, Louisville, KY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Coultas","sequence":"additional","affiliation":[{"name":"Kala Pharmaceuticals, Inc, Watertown, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Brazzell","sequence":"additional","affiliation":[{"name":"Kala Pharmaceuticals, Inc, Watertown, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,8,7]]},"reference":[{"key":"R1-20250728","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ajo.2013.12.023","article-title":"Dry eye in the Beaver Dam Offspring Study: prevalence, risk factors, and health-related quality of life","volume":"157","author":"Paulsen","year":"2014","journal-title":"Am J Ophthalmol."},{"key":"R3-20250728","first-page":"93","article-title":"The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye Workshop","volume":"2","year":"2007","journal-title":"Ocul Surf."},{"key":"R5-20250728","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/archophthalmol.2011.364","article-title":"Dry eye disease: an immune-mediated ocular surface disorder","volume":"130","author":"Stevenson","year":"2012","journal-title":"Arch Ophthalmol."},{"key":"R6-20250728","doi-asserted-by":"crossref","first-page":"DES192","DOI":"10.1167\/iovs.17-23651","article-title":"Inflammatory response in dry eye","volume":"59","author":"Yamaguchi","year":"2018","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"R9-20250728","doi-asserted-by":"crossref","first-page":"589875","DOI":"10.1100\/2012\/589875","article-title":"The dry eye disease activity log study","volume":"2012","author":"Iyer","year":"2012","journal-title":"Sci World J."},{"key":"R10-20250728","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/02713683.2012.757323","article-title":"Effectiveness of dry eye therapy under conditions of environmental stress","volume":"38","author":"Tomlinson","year":"2013","journal-title":"Curr Eye Res."},{"key":"R11-20250728","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1167\/iovs.12-11361","article-title":"Influence of a controlled environment simulating an in-flight airplane cabin on dry eye disease","volume":"54","author":"Teson","year":"2013","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"R12-20250728","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ajo.2014.01.001","article-title":"Dry eye exacerbation in patients exposed to desiccating stress under controlled environmental conditions","volume":"157","author":"L\u00f3pez-Miguel","year":"2014","journal-title":"Am J Ophthalmol."},{"key":"R13-20250728","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul Surf."},{"key":"R14-20250728","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1167\/tvst.4.3.11","article-title":"Topical ocular drug delivery to the back of the eye by mucus-penetrating particles","volume":"4","author":"Schopf","year":"2015","journal-title":"Trans Vis Sci Tech."},{"key":"R15-20250728","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S1542-0124(12)70053-8","article-title":"Development and validation of a short global dry eye symptom index","volume":"5","author":"Schaumberg","year":"2007","journal-title":"Ocul Surf"},{"key":"R16-20250728","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ajo.2004.04.052","article-title":"A randomized, double-masked, placebo-controlled multicenter comparison of loteprednol etabonate ophthalmic suspension 0.5% and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance","volume":"138","author":"Pflugfelder","year":"2004","journal-title":"Am J Ophthalmol."},{"key":"R17-20250728","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ophtha.2014.11.006","article-title":"Effects of corneal nerve density on the response to treatment in dry eye disease","volume":"122","author":"Kheirkhah","year":"2015","journal-title":"Ophthalmology."},{"key":"R18-20250728","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ejpb.2015.02.032","article-title":"Undefined role of mucus as a barrier in ocular drug delivery","volume":"96","author":"Ruponen","year":"2015","journal-title":"Eur J Pharm Biopharm."},{"key":"R19-20250728","first-page":"299","article-title":"Development of a non-settling gel of 0.5% loteprednol etabonate for anti-inflammatory use an ophthalmic drop","volume":"7","author":"Coffey","year":"2013","journal-title":"Clin Ophthalmol."},{"key":"R20-20250728","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/14656566.2018.1439920","article-title":"Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid","volume":"19","author":"Comstock","year":"2018","journal-title":"Expert Opin Pharmacother."},{"key":"R21-20250728","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0960-0760(91)90120-T","article-title":"Soft drugs. 10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate","volume":"38","author":"Druzgala","year":"1991","journal-title":"J Steroid Biochem Mol Biol."},{"key":"R22-20250728","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3109\/02713689109020329","article-title":"Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes","volume":"10","author":"Druzgala","year":"1991","journal-title":"Curr Eye Res."},{"key":"R23-20250728","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bcp.2016.12.010","article-title":"Identification of esterase involved in the metabolism of two corticosteroid soft drugs","volume":"127","author":"Samir","year":"2017","journal-title":"Biochem Pharmacol."},{"key":"R24-20250728","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jcrs.2019.03.023","article-title":"An algorithm for the preoperative diagnosis and treatment of ocular surface disorders","volume":"45","author":"Starr","year":"2019","journal-title":"J Cataract Refract Surg."}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000002452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T22:07:31Z","timestamp":1753740451000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000002452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,7]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0000000000002452","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,7]]},"assertion":[{"value":"2020-04-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}